Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
08 sept. 2021 00h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion to Participate in Upcoming September Investment Conferences
02 sept. 2021 00h20 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
12 août 2021 16h05 HE
|
Angion Biomedica Corp.
-- Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demonstrated ANG-3070 was well-tolerated across dose cohorts, achieving drug...
Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
03 août 2021 00h05 HE
|
Angion Biomedica Corp.
ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney...
Travere Therapeutics Reports Second Quarter 2021 Financial Results
29 juil. 2021 16h01 HE
|
Travere Therapeutics, Inc.
Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track...
Travere Therapeutics to Report Second Quarter 2021 Financial Results
22 juil. 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close...
Vera Therapeutics Appoints Sean Grant as Chief Financial Officer
14 juil. 2021 07h30 HE
|
Vera Therapeutics
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021
04 juin 2021 08h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high...
Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
02 juin 2021 08h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is...
Travere Therapeutics to Present at Upcoming Investor Conferences
27 mai 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...